NCT03367052 is a NA clinical trial of Two level Prodisc-C vivo in Cervical Disc Disease, sponsored by Peking University People's Hospital.

Who is sponsoring NCT03367052?

NCT03367052 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT03367052?

Interventions in NCT03367052: Two level Prodisc-C vivo, Hybrid.

What condition does NCT03367052 study?

NCT03367052 studies Cervical Disc Disease.

Is NCT03367052 still recruiting?

NCT03367052 is currently status unknown. Last updated 8 December 2017.

Last reviewed 2017-12-08 · How we verify

NCT03367052

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical and Radiological Outcomes: Two-level Cervical ProDisc-C Vivo Versus Hybrid Construct.

Status unknown NA Last updated 8 December 2017

What this trial tests

NA trial testing Two level Prodisc-C vivo in Cervical Disc Disease in 542 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	542
Start date	1 January 2018
Primary completion	1 December 2025
Estimated completion	1 December 2025

Drugs / interventions tested

Two level Prodisc-C vivo
Hybrid

Conditions studied

Cervical Disc Disease — all drugs for Cervical Disc Disease →

Sponsor

Peking University People's Hospital

Who can join

Adults 20 to 70, any sex, with Cervical Disc Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to investigate the clinical and radiological results of two-level cervical ProDisc-C vivo versus hybrid construct.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cervical Disc Disease

Currently open trials in the same condition.

NCT04623593 — Cervical Arthroplasty Cost Effectiveness Study (CACES) · NA · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03367052 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 8 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03367052.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing